Department of Dermatology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Departments of, Department of, Dermatology, Royal Marsden NHS Foundation Trust, London, UK.
Clin Exp Dermatol. 2021 Mar;46(2):338-341. doi: 10.1111/ced.14469. Epub 2020 Oct 22.
Checkpoint inhibitor (CPI) therapy has significantly improved overall survival for metastatic melanoma, and is now approved for use in the adjuvant setting. Modulating the immune system is recognized to cause cutaneous immune-related adverse events (irAEs). We conducted a retrospective observational cohort study of adult patients with melanoma at our tertiary referral centre, who received CPI therapy from 2006 to March 2018. This is the single largest study of cutaneous irAEs occurring on CPI therapy in patients with melanoma to date and encompasses 12 years. The results showed that cutaneous toxicity occurs in 24% of patients but is generally manageable, with < 5% patients discontinuing treatment.
检查点抑制剂（CPI）治疗显著改善了转移性黑色素瘤的总生存期，目前已批准用于辅助治疗。调节免疫系统被认为会引起皮肤免疫相关不良事件（irAEs）。我们对 2006 年至 2018 年 3 月在我们的三级转诊中心接受 CPI 治疗的黑色素瘤成年患者进行了一项回顾性观察队列研究。这是迄今为止针对黑色素瘤患者 CPI 治疗中发生的皮肤 irAEs 进行的最大规模的研究，涵盖了 12 年。结果表明，24%的患者出现皮肤毒性，但通常可管理，<5%的患者停止治疗。
